Gisens Biotech
Gisens Biotech builds portable graphene-biosensor monitors for chronic kidney disease patients.
- Pre-Seed
Gisens Biotech builds portable graphene-biosensor monitors for chronic kidney disease patients.
Two advantages over the centralized laboratory hold up under published measurement: a quantitative read of urea, potassium, sodium and chloride from saliva or serum without a sample sent to a lab, and precision that the April 2024 Analytical Chemistry study found similar to or better than benchtop analyzers while the device stays portable.
The reported numbers support that judgment, with accuracy above 95.5% and coefficients of variation below 9%, and diagnostic sensitivity of 99.7% for urea, 97.6% for potassium, 99.1% for sodium and 89.0% for chloride.
A third advantage belongs to the platform rather than to one panel, because the same graphene transistor was carried beyond electrolytes into a hepatitis E antigen immunoassay by late 2025, where machine-learning augmentation lifted sensitivity and specificity from 89% and 69% to 100% and 100%.
Source: pubs.acs.org
The clearest risk is execution against a large incumbency, because kidney function testing in 2024 was still performed in centralized laboratories and hospitals with benchtop autoanalyzers, and the monitoring platform has to win over an installed workflow rather than on price alone.
Funding scale is the second constraint, as the recorded rounds of $420,000 and $20,000 size the company for a development programme rather than a commercial launch.
A third risk is research dependence, since the platform's published validation is the work of a two-institution team, with the April 2024 and July 2024 papers listing affiliations both at Universidad Nacional de La Plata with CONICET in La Plata, Argentina and at the company's own bioelectronics department in Berkeley.
Source: advanced.onlinelibrary.wiley.com